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Aberrant cytoplasmic expression of the p16 protein in
breast cancer is associated with accelerated tumour
proliferation
R Emig', A Magener2, V Ehemann', A Meyer2, F Stilgenbauer3, M Volkmann3, D Wallwienerl and H-P Sinn2
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Summary The p16 protein plays an important role in the transition of cells into the G, phase of the cell cycle. We have studied the prevalence
of p16 protein expression in breast carcinomas in a prospective series of 368 invasive and 52 non-invasive malignancies, as well as in 88
locally recurring tumours and three tumour cell lines. p16 protein expression was evaluated immunohistochemically on paraffin sections using
monoclonal and polyclonal anti-pl6 antibodies. and by immunoblotting of tumour cell suspensions. Tumour cell lines were also subjected to
polymerase chain reaction-single strand polymorphism (PCR-SSCP) analysis and direct DNA sequencing. The results were compared with
established prognostic parameters, DNA flow cytometry and p53 protein expression. In 33 (90o) invasive and two (40O) intraductal
carcinomas, a cytoplasmic accumulation of the p16 protein was seen. These cases were characterized by poor histological grade of
differentiation. loss of of oestrogen receptors and progesterone receptors and frequent overexpression of the p53 protein. In addition, breast
carcinomas with aberrant p16 expression demonstrated a high proliferative activity, with median S-phase fractions 740,o higher than in the
control group and the median Ki67 fractions elevated to 75%. A genetic alteration of the p16 gene was not detectable in three analysed cell
lines with cytoplasmic p16 expression applying PCR-SSCP and direct DNA sequencing. These results indicate that cytoplasmic accumulation
of the p16 protein identifies a subset of highly malignant breast carcinomas with accelerated tumour proliferation and other unfavourable
parameters in breast cancer. The described protein accumulation is apparently not caused by an alteration of the p16 gene.
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The cell cvcle is regulated by a number of cyclin-dependent
kinases (CdKs). A number ofdifferent proteins inhibit the progres-
sion through the cell cycle by interference with the CdKs. a
phenomenon especially interesting in malignant cells. Amonc
these proteins are: p27. induced mainlv by cell-cell contact: p2l
(WAF-1. CIPI. CDI1). activ-ated by the tumour-suppressor gene
p53 (Pines. 1994: Mousses et al. 1995): and p16 (CDKN2. MfTS I
which inhibits CdK4.
p16. located on chromosome 9p21. is considered toplay an impor-
tant role as a tumour-suppressor gene (Serrano et al. 1993: Kamb et
al. 1994). In cell lines ofdifferent tumour types. such as lung cancer.
bladder tumours and lymphatic leukaemia. genetic changes in chro-
mosome 9p2 1 have been described in 30-85%7 ofcases (Nobori et al.
1994: Xu et al. 1994). In fresh solid tumours. the incidence ofgenetic
alterations. such as the homozvgous deletion of p]6. is only in
10-20%. Some studies have been performned to elucidate the role of
p16 in breast cancer. applyincg polymerase chain reaction-single
strand polymorphism (PCR-SSCP). Southem blot analysis and other
techniques on cell lines and breast carcinoma samples (Kamb et al.
1994: Bems et al. 1995: Quesnel et al. 1995). It was concluded that
gene alterations of CDKN2 and the occurrence ofgenetic damage to
the CDKN2 gene in breast cancer are rare events and are notlikelyr to
be mxvolxed in the carcinogenesis and progression of breast cancer.
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Hovwever. a recently published report demonstrated that inactixvation
ofpi6 occurs in 33%7c ofbreast cancer cell lines because of aberrant
or de novo 5'CpG island methylation ofp16 (Herman et al. 1995).
Few- data pertain to the immunohistochemical detection of p16
alterations in malignant cells. A loss of expression of p16 during
the inxasixe stage of tumour progression w-as obserxed in
melanocvtic lesions (Reed et al. 1995).
Immunohistochemistrv is an established method used to analx-se
expression and accumulation ofmany different proteins, including
tumour-suppressor genes. In this context. accumulation of the p53
protein has been shown to be due to alterations ofthe gene (Finlay
et al. 1988.) Based on the knowledge ofthe role ofp16 andp53 in
cell cycle control. we haxe analysed both the p53 and p16 protein
expression in this study and compared the results Awith the rate of
tumour proliferation (as determined by flow cvtometrx and calcu-
lation of the Ki67 expression detected by immunocvtochemistn-w.
We further correlated these findinas to established prognostic
factors such as grading. tumour type. Iymph node in olvement.
oestrogen and progesterone receptor status and other prognostic
factors such as Bcl-2. c-ErbB-2 and retinoblastoma (RB). detected
bx immunohistochemistr-. Our results indicate that in a subset
of breast carcinomas oxverexpression of the p16 gene product is
associated w-ith rapid cell proliferation.
MATERIALS AND METHODS
Tumour specimens and immunohistochemical staining
Five hundred and tmelxve breast carcinomas from patients w-ho were
treated in 1995 and 1996 at the Unixersitv Women's Hospital of
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Table 1 Tumour type, stag and histdogilca grade of maklroncy of
nvaisive breast cancers stuied, and protein accuntdation of p16 and p53
(categories ftat are 'not aplcable' are not listed; n.s. idicates P-values
statistiall not gnci)
Tota p16 piaWn p53 proWn
-- --n on
Median age (years) 53.7 52.2 552
P-value n.s. n.s.
Tumourtype
IDC 292 28 58
ILC 48 2 5
Medury 3 3 3
Other (m us, papillary, tbular) 25 0 1
P-value (IDC vs. ILC) n.s. n.s.
pT category
pT1 170 18 27
pT2 158 10 29
pT3 17 1 3
pT4 12 0 3
P-valie (pT1 vs pT2-4) n.s. n.s.
pN category
pNO 185 14 28
pNl 136 14 28
pN2 10 0 2
P-value (pNO vs. pN1,2) n.s. n.s.
Tumour grading
Gl 56 0 0
G2 180 3 16
G3 119 25 45
P-value (G1,2 vs. G3) <0.0001 <0.0001
Heidelberg wereexamined, including 368 invasivepimary cancers,
52 intaductal carcinomas (DCIS) and 88 locoregional tumour
recurrences. All tumours wereclassified according tothe AFIPclas-
sification for brast carinomas (Rosen and Oberman, 1992) and
staged acoding to the TNM system (UICC, 1992) (fordetails see
Table 1). Tumour tissue was fixed in buffered formalin for at least
24 h, and suequently embedded in paraffin and cut into tissue
sections ofapproximately 2 tm These sections weredepaaffinized
by incubation at 370C for24 h. Afterincubation at500C foranother
30 mn, the sections were immersed in xylene for 2 x 10 in,
followed by rehydration thrugh a graded series ofethanol (100%,
96%, 70% each for 5 min). Before immunohistochemical staining,
the tissue sections underwent a microwaving procedure for 10 min
at a high energy setting. After the addition of 50 ml of distilled
water, an additional 7 min of high microwave energy was applied
after addition of a diluted antigen retrieval buffer (Dako, Glostrup,
Denmark). The slides were allowed to cool offat room temperature
for a minimum of 20 min and sections stained using an automated
immunohistochemical technique (Biotek TechMate, Biotek
Solutions, Newport Beach, CA, USA) with strict adherence to the
stainng protocol. In brief, primary antibodies were applied for
30 min, followed by an indirect septavidin biotin method with
30 mm ofseondary goat anti-mouse antibody and 45 min ofstrep-
tavidin biotin conjugate. Pimary antibodies used for detection of
the p16 antigen were the mouse monoclonal antibody G175-405
(dilution 1:200, PharMingen, San Diego, CA, USA), and a rabbit
polyclonal antibody (1:500, PharMingen). Other monoclonal anti-
bodies used were anti-p53 antibody D07 (1:100, Dako), anti-Ki67
antibody MIB1 (1:200, Dianova, Hamburg, Germany), anti-c-erbB-
2 antibody 3B5 (1:2000, Oncogene Science, Manhasset, NY, USA),
anti-bcl-2 antibody 124 (1:100, Dako) and anti-retinoblastoma anti-
body G3-245 (1:500, PharMingen). Oestrogen and progesterone
receptors were detected with monoclonal antibody ID5 for the
oestrogenreceptorand apolyclonal rabbit-anti-human antibody for
the progesterone receptor (both 1:100, Dako).
MI I evaluation of immunohistochemistry
The antibody staining was evaluated by two observers and
recorded as the proportion of tumour cells positive for the evalu-
ated antibodies. p16 expression was recorded separately as the
percentage ofpositive tumour nuclei and, ifpresent, an additional
estimation of the percentage of tumour cells with cytoplasmic
antigen expression. p53 expression and MiB1 (Ki67) staining
were also registered as the percentage of nuclei staining strongly
for the p53 or MiB1 proteins with regard to the total number of
tumour nuclei in at least two high-power fields at the tumour
invasion front. c-erbB-2 immunoreaction was scored from 0 to 4,
considering merely cell membrane staining. Bcl-2 expression was
considered positive if at least 15% of tumour cells were stainedx
Oestrogen and progesterone receptor staining was evaluated for
staining intensity and number of positive nuclei (Remmele and
Stegner, 1987), receptor positivity was assumed when the semi-
quantitative score was at least three points (out of a maximum of
12 points).
Flowcytomefty
Tumour samples routinely underwent a cell cycle analysis using
DNA flow cytometry as described elsewhere (Feichter et al, 1988.
1989). Briefly, tumour samples were thoroughly minced with scis-
sors. The nuclei were extracted at room temperature by incubation
in acid pepsin (3000 u mg-', Serva, Heidelberg, Germany)
dissolved in 100 ml of 0.9 M sodium chloride containing 0.25%
hydrochloric acid and carefully stirring for 20 min. After 30 s of
sedimentation, 0.5 ml of the supernatant cell suspension was
suspended in 1 tg ml-' 4',6-diamindino-2-phenylindole (DAPI)
dissolved in Tris-buffer pH 7.8. Minimum incubation time was
30 min. Flow cytometry was carried out using a PAS II flow
cytometer equipped with a high-pressure mercury lamp (Partec,
Munster, Germany) using the following filters: KG 1, BG 38 and
UG 1 for excitation; TK 420 as dichroic mirror, and GG 435 as
barrier filter. A flow rate of about 100 counts s-' was maintained
by vacuum adjustment. DNA histograms ofat least 10 000 counts
were ploted. The DNA index ofaneuploid cells was expressed as
the relative modal DNA value of the aberrant peak in relation to
the diploid one. Normal human lymphocytes with a coefficient of
variation (CV) of 1.0 were used forcalibration ofthe diploid peak.
The cell cycle-phase distribution patterns of the diploid and
aneuploid umours were calculated using the Multi-cycle software
package (Phoenix Flow Systems, San Diego, CA, USA) after
adjustments were made for debris and aggregation (nuclear
doublets and triplets).
Immunobkblng oftissue samples and cell lines
Cryopreserved breast cancer tissue samples were obtained from
our tumour bank. Three tumours (nos 180, 301 and 304) were
selected because oftheir known cytoplasmic expression ofp16 as
detennined by paraffin immunohistochemistry. A fourth tumour
(no. 300, not positive for p16 staining) was selected as a negative
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Table 2 p16 and p53 protein accumulation in intraductal. invasive and
recurrent breast cancer
p16 protein p53 protein Total
accumulaton accumulaton
n(%) n(%)
DCIS, non-cornedo type 0 5 (17) 29
DCIS, comedo type 2 (9) 9 (39) 23
Invasive carcinxma 33 (9) 82 (22) 368
Locoregional recurrence 12 (14) 29 (33) 88
control. Established tumour cell lines were also used. HeLa
(human epithelioid cervical carcinoma cell line) and CaSki
(human cervical epidermoid carcinoma cell line) as positive
controls with known high amounts of p16 protein and MCF-7
(human breast adenocarcinoma cell line) as negative control (Tam
et al. 1994).
Adherent growing cell lines were cultured in DMEM
(Dulbecco's modified Eagle medium). harvested by washing in
physiological phosphate-buffered saline (PBS). scraped into
Falcon tubes after another application of 20 ml of PBS. and spun
down at 1400 r.p.m. The pellet was transferred into lysis buffer
containingy 50 mmol of Tfis-HC1 pH 8.0. 150 mmol of sodium
chloride. 1% NP 40 + pepstatin. pefablock and leupeptin. The
samples were incubated on ice for 30 min followed by homogen-
ization with a pestle for 10-12 times. Lysates were centrifuged at
14 000 r.p.m. at 5 C. and the supematant used forimmunoblotting.
Tissue samples from crvopreserxed breast cancers (150-
200 mg) were minced and homogenized in lysis buffer as specified
above. Solid particles were sedimented. the supematant was
centrifuged at 14 000 r.p.m. at 5°C and also underwent 'gel
electrophoresis.
One volume of protein homogenate was heated at 95°C for
10 min with two volumes ofsample buffer containing S-mercapto-
ethanol. Equal amounts of protein were then subjected to electro-
phoresis in 12.5% sodium dodecyl sulphate (SDS) minigels at 20
mA. Proteins were transferred onto an Immobilon membrane
(Millipore) in a Trans-Blot SD semi-dry transfer cell (Bio Rad) at
150 mA for 30 min. After blotting, the membrane was washed
several times in PBS/0.05% Tween. and blocked for 1.5 h in
PBS/0.05% Tween containing 0.2% bovine serum albumin (BSA).
Subsequently. the membrane was incubated with primary poly-
clonal rabbit anti-human p16 antiserum (PharMingen. 1:1000. in
0.05% c-BSA/PBS/Tween) overnight. The secondary antibody
(horseradish peroxidase-conjugated goat anti-rabbit IgG.
Stratagene) was applied for 60 min. the membrane wvashed and
treated according to the enhanced chemiluminescence (ECL)
protocol (Boehringer. Mannheim. Germany). The radiographic
film was exposed to the chemiluminescence membrane for up to
30 mmn.
PCR-SSCP
Genomic DNA of three breast cancer cell lines established in our
institution (two showing p16 protein accumulation) was isolated
by detergent-mediated lysis and column chromatography as previ-
ously described (Volkmann et al. 1994). For controls. DNA prepa-
rations from different cell lines were used. HUH7 (hepatocellular
Table 3 Correlation of p16 protein accumulation in invasive breast
carcinomas with other immunohistochemical tumour markers (absolute
numbers of cases are stated)
No p16 protein p16 protein P-value
accumulaion accumulaton
p53
Negative (< 20% positive nuclei) 286 15 <0.0001
Positive (> 20% positive nuclei) 49 18
bcl-2
Negative (< 15% tumour cells) 102 24 <0.0001
Positive (> 15% tumour cells) 261 9
c-erbB-2
Negative (score 0,1) 278 26 0.54
Positive (score 2-4) 57 7
Oestrogen receptors
ER negative (score 0-3) 72 24 <0.0001
ER positive (score 4-12) 259 6
Progesterone receptors
PR negative (score 0-3) 129 25 <0.0001
PR positive (score4-12) 199 5
carcinoma) and HepG2 (hepatoblastoma) have a p16 wild-type
status. HL60 (human acute myeloid leukaemia). known to carex a
point mutation in exon 2. and the line DLDI (colon carcinoma)
with a mutation in exon 1 of the pl6 gene served as mutant
controls. Cell lines were obtained from DSM (Braunschweig.
Germany). Exons 1 and 2 ofthepl6 grene were screened for muta-
tions by radioactive SSCP because no relevant mutations have yet
been described in exon 3. which is only 11 bp large. PCR primers
were used as described elsewhere (Okamoto et al. 1994a: Borg et
al. 1996). PCR was carried out with incorporation of [V'P]dCTP
(Hartmann Analytic. Braunschweig. Germany). with 5%7 DSMO
and 0.1 mg ml-' BSA included. PCR conditions on the Perkin
Elmer 480 Thermal cycler were: 35 cycles consisting of 92'C for
30 s. 58°C/62°C for 1 min. and 72°C for 1 min. Samples were
denatured and underwent electrophoresis under non-denaturing
conditions for autoradiography as previously described.
Direct DNA sequencing
Direct DNA sequencing was performed on a Perkin-Elmer ABI-
377 sequencer (ABI Prism) using a dye terminator cycle
sequencing ready reaction kit (Perkin-Elmer. Weiterstadt.
Germany). After purification using Quiaquick purification kit
(Quiagen. Dassel. Germany). pl6 sequencing was performed
using the same primers as for initial amplification.
Statistics
Classified values were tested using the two-sided chi-squared test
or Fisher's exact test for dichotomous Xariables. Continuous
values were compared statistically by the Mann-Whitney
rank-sum test. P-values of 0.05 or less were considered statisti-
cally significant. Multix ariate analysis was performed by applying
a logistic regression model and stepw-ise regression. All calcula-
tions were made with S-PLUS 3.3 (StatSci Dix ision. MathSoft.
Seattle. WA. USA).
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Figure 1 Intraductl breast carcinoma, comedo type (A-C) and invasive ductal carcinoma (D-F). Both tumours display cytopbasmic p16 protein accumulation
(A and D), p53 protein accumulation (B, E) and a high fracfion of Ki67 expressing tumour cells (C and F)
RESULTS
Immunohistology of p16 expression in tumours
The pattern of p16 expression of the tumour cells was classified
into nuclear positivity. cytoplasmic expression and lack of p16
expression. Most frequently. nuclear expression was observed in
10-100% of tumour cell nuclei ( 176 cases. 47.8%). In another 154
cases, tumour nuclei were only weakly positive or no reaction was
detectable. while nuclear p16 reaction was preserved in the
surrounding benign tissue. Reaction patterns were compared
between the monoclonal and the polyclonal antibodies on a case to
case basis. and nuclear p16 reaction often proved to be weaker or
absent using the monoclonal p16 antibody as opposed to the poly-
clonal antiserum. Neither the presence and percentage of p16 posi-
tive nuclei nor the lack ofdetectable p16 staining was statistically
correlated with tumour differentiation. tumour size. grade of
differentiation or proliferation parameters (data not shown) and.
therefore. this was not further analysed.
A third pattern of pl6 reactivity. a strong and diffuse cyto-
plasmic staining in at least 50% ofthe tumour cells. was seen in 33
invasive pnmary breast cancers (out of a total of 368 invasive
tumours. 9.0%). and five cases were weakly positive for
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Figure 2 Box-whisker plot showing the percentage of Ki67-postve tumour nuclei (left), and S-phase (SPF) and G2M-Phase (G2M) fraCtions (midde and right)












Figwe 3 Box-whisker plotshowin the pene of K67 si tumnour nucei (left), and S-phase (SPF) and G2M pase (G2M) fraction (midde and right)
in relaion to the nudearacmuabon of the p53 protein
cytoplasmic p16 expression (less the 50% of tumour area). No
cytoplasmic staining of p16 was observed within the umour
stroma or the surrounding mammary tissue. In all 33 cases
displaying p16 expression, at least 50% oftumour cells were posi-
tive using both the monoclonal antibody and the polyclonal anti-
serum. All tumours with cytoplasmic p16 expression were also
positive forp16 within a variable number oftumour cell nuclei.
In intraductal breast carcinomas (DCIS), a lower percentage of
p16 expression was found. Cytoplasmic expression of p16 was
observed in only 2 out of 52 intraductal carcinomas, both cases
being grade 3 tumours of comedo type (Table 2). A concordant
cytoplasmic p16expression ofthe intraductal and invasive tumour
component was observed when both components were present
within one tumour. When compared with the primary carcinomas,
cytoplasmic p16 expression was seen more often in the locally
recurrent tumours (12 of 88 cases, 14%); however, this difference
is not statistically significant at the 5% level.
Frequently, a simultaneous overexpression of the p53 antigen
(using 20% p53 positive tumour nuclei as the cut-off value) was
present in tumours displaying cytoplasmic p16 expression.
Overexpression of both antigens was demonstrated in more than
50% of the primary tumours (20 out of 33 cases), in 7 out of 12
locoregional recurrences, and in one of the two intraductal carci-
nomas. When compared with the overall frequency ofp53 protein
overexpression, the association of p16 overexpression and p53
overexpression was statistically highly significant (Table 3).
Examples of invasive and non-invasive breast carcinomas with
simultaneous p16 and p53 overexpression and a high proliferative
activity are shown in Figure 1. In addition, tumours overex-
pressing p16 orp53 antigens shared a number ofhistopathological
features. In most cases, these tumours were invasive ductal carci-
nomas with a high grade of malignancy (Table 1). However, for
both tumour suppressor antigens, no relationship to tumour type,
size (pT category) or nodal status (pN category) was observed.
Brffish JournalofCancer(1998) 78(12), 1661-1668 0CancerReseard7 Campaign 19981666 R Emig etal
Tab 4 Pkoidy of bxnour cells as detern by DNA flowcytomety and
accumulation of p16 or p53 p in nasive breast cerc mas (absokte
runber of cases are stated, evakuWae cases only)
p16 prin p53 proein Totd
acCMu_on acwnub
Diploid (Di= 1) 0 7 97
Aneupkid (Dl> 1-Di <2) 18 42 142
Tetapkid(Di= 2) 3 6 20
Hypertetooid(Dl>2) 3 7 19




FIgure 4 lmnwblot sh g distin reacbon at 16 IdDa for ce lines
HeLa, CaSli, and tumnour 180, 301 and 304 corresponrxn to cytoplasmic
p16 protein accumulation seen wftlin these tumnours
Interestingly, the RB protein was not detectable in the majority
of tumours showing cytoplasmic p16 expression (23 tumours).
This is remarkable because the RB protein was detectable in ahigh
percentage of tumour cell nuclei in poorly differentiated breast
cancers. Only 35% of these were negative for RB expression.
Tberefore, the loss of RB expression occurs more frequently in
tumours showing cytoplasmic p16 expression.
Other differentiation antigens typically expressed in breast
cancers, such as bcl-2, oestrogen receptor (ER) and progesterone
receptor (PR), were detectable in only a minority of p16 over-
expressing carcinomas (20-27% of p16-positive tumours, all
P<0.001 compared with the cytoplasmically p16-negative
tumours, Table 3). No relationship of p53 or cytoplasmic p16
overexpression with c-erbB-2 expression was observed.
Proliferaion parametrs of p16- and p53-positive
tumours
The proliferative activity of individual tumours was assessed by
determining the Ki67 proliferation index and by DNA flow cytom-
etry. Tumours overexpressing the p16 or p53 antigens showed a
highly significantly elevated Ki67 index as compared with the
control group (both P<0.0001, Wilcoxon rank-sum test). The
median Ki67 index was 60% for tumous with >20% p53-positive
cell nuclei and 70% for tumours with 250% cytoplasmic p16
expression, in contrast to 15% and 20% for the non-p53 and non-
p16 overexpressing tumours (Figures 2 and 3).
The median S-phase fraction, as determined by flow cytometry,
values were 6.7% for tumours with cytoplasmic p16
staining and 4.6% for tumours with >20% p53 staining (Figures 2
and 3), as compared with 4.1% and 4.05% in the control group
(P = 0.0027 and P = 0.2, Wilcoxon rank-sum test). Cytoplasmic
p16 overexpression had no influence on G2M4 frctions, but G,M
was significantly elevated in p53-positive carcinomas (P = 0.015).
All tumours with cytoplasmic p16 expression proved to be aneu-
ploid, the majority had DNA indices between 1 and 2 (Table 4).
Three tetraploid and three hypertetraploid tmours were docu-
mented. A similar distribution was found for p53 overexpression.
To determine which immunohistological and DNA cytometric
factors are independently predictive of aberrant p16 expression,
all parameters that were significant in univariate analysis were
entered into a multivariate logistic regression model. After step-
wise selection, only tumour grading, S-phase fraction, oestrogen
receptorexpression andp53 expression were determined as signif-
icant and independent parameters for the prediction of aberrant
p16expression.
Immunobkting of cell lines and tssue samples
Fmdings obtained by Westem blotting confirmed immunohisto-
logical results obtained with the same cell lines and tissue samples.
Three tumours that displayed cytoplasmic expression of p16 in
immunohistochemistry were also positive in the immunoblot
Both p16-positive cell lines also displayed distinct bands at
16 kDa in Westem blot analysis (Figure 4).
PCR-SSCP and diect DNA sequencing
No evidence for p16 mutations in the tumour-derived cell lines
could be detected using PCR-SSCP and direct DNA sequencing
(data not shown). However, tiese data do not exclude the presence
ofhomozygous deletions.
DISCUSS
As demonstrated by flow cytometry and other techniques, breast
cancers are generally slowly proliferating tumours compared with
other human malignancies (Hedley, 1993; Sinn et al, 1997).
However, a subset of mammary carcinomas displays an acceler-
ated proliferation. Different mechanisms are known to be respon-
sible for the loss of cell cycle control, most importantly the
inactivation oftumour-suppressor genes in conjunction with acti-
vation ofcyclin-dependent kinases and cyclins (Hunter and Pines.
1994; Sherr, 1994). The classical mechanism of inactivation of
tumour-suppressor genes in carcinogenesis is through homozy-
gous inactivation ofboth alleles and was elucidated in retinoblas-
toma(Goodrich andLee, 1993). Inactivation oftumour-suppressor
genes may occurthrough different mechanisms, as is the case with
p53, and may lead to overexpression of the protein (Nigro et al,
1989; Lane, 1992). p53 overexpression was found to be associated
with hyperproiferation ofthe tumours (Isola et al, 1992; Allred et
al, 1993). Thep16tumour-suppressor gene is known to be vital for
the regulation ofthe cell cycle at the G1 checkpoint (Kamb, 1995;
Koh et al, 1995; Enders et al, 1996), but little is known about
possible p16 alterations in breast cancer. In contrast to other
tumour-suppressor genes, point mutations of the p16 gene were
detected only sporadically in primary breast carcinomas (Xu et al,
1994; Quesnel et al, 1995). However, a high percentage of
homozygous pi6 deletion was observed in breast cancer cell lines
(Kamb et al, 1994; Xu et al, 1994; Cairns et al, 1995). Recently,
another mechanism ofp16 inactivation, hypermethylation of the
pi6 promoter region, was described in breast carcinoma (Herman
et al, 1995; Merlo et al, 1995).
Ontheprotein level, evidence has shown thatthe p16protein may
be inactivated in up to 49% ofprimary breast carcinomas (Geradts
and Wilson, 1996). This immunohistochemical observation has also
been made in head and neck carcinomas (Reed et al, 1996) and
malignant melanoma (Reed et al, 1995). In addition to this apparent
loss of p16 expression. we have observed a small percentage of
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breastcarcinomas with an aberrantcytoplasmic accumulation ofthis
protein, a finding previously described only in breast carcinoma cell
lines (Okamoto et al. 1994b/, Geradts et aL 1995). Human cell lines
lacking functional retinoblastoma protein (pRB) were found to
contain high levels ofpl6 RNA and protein. suggesting a negative
feedback loop by which pRB might regulate p16 expression in late
G, phase of the cell cycle (Hara et al. 1996). The product of the
CDKN2 gene (pl6) inhibits phosphorylation of the retinoblastoma
protein (pRB) and thus acts as a negative cell cycle regulator.
Consequently, an inverse relationship has previously been described
for p16 protein levels and RB expression in human cell lines (Hara
et al, 1996; Maelandsmo et al, 1996). Our data suggest a similar
relationship between pRB expression and p16 protein accumulation
for pnrmary breast cancers because we observed a frequent loss of
pRB expression in tumours with accumulation of the p16 protein.
On a functional basis, our results also suggest that this aberrant
expression of p16 is associated with concurrent loss of its function
and hyperproliferation ofthe tumourcell. The unusually high prolif-
eration rate of tumours with cytoplasmic p16 expression seems to
indicate an underlying defect of the p16 gene or some other gene.
because there were no alterations detectable with PCR-SSCP and
direct DNA sequencing techniques in the pl6 gene itself in the
tumour cell lines tested. As mentioned above. this altered gene may
be the RB gene. The accumulation ofp16 protein may also be due to
some kind of disturbance related to the normal function of the
protein. or to a defect of the pi6 gene that is not detectable by the
techniques applied in this study. On a morphological basis. tumours
with stabilization ofthe p53 protein are different from tumours with
p16 protein stabilization because p53 accumulation occurs typically
in the nucleus, while p16 accumulation was seen within the cyto-
plasm. However, both in tumours with p53 or with p16 accumula-
tion, the S-phase fractions were elevated, had poor grade of
differentiation and the loss of hormone receptors was common.
These observations and the lack of correlation with lymph node
status and tumour size were described for breast carcinomas with
p53 accumulation previously (Friedrichs et al. 1993; Beck et al.
1995; Charpin et al. 1995). Therefore, it appears that aberrant
expression of the pl6 or p53 proteins are very early changes in the
progression of breast carcinoma. and do not change significantly
with tumour progression.
In summary. we have demonstrated that there is a subset of
poorly differentiated. rapidly proliferating and ER/PR-negative
breast cancers that show aberrant cytoplasmic p16 accumulation as
detected by immunohistochemical staining. Therefore, accumula-
tion of the p16 protein could serve as an important biological
markerforthe identification ofhighly malignant breast carcinomas.
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